Viewing 36-55 of 140 articles
ASCO 2018: Results for 2nd-line Therapy: A Cross-over Trial, Abiraterone + Prednisone vs Enzalutamide for Patients Metastatic Castration-Resistant Prostate Cancer
ASCO 2018: Active Surveillance in the Real World: What Have ProtecT and Other Prospective Trials Taught Us?
ASCO 2018: A Prospective Phase 2/3 Multicenter Study of 18F-DCFPyL PET/CT Imaging in Patients with Prostate Cancer: Examination of Diagnostic Accuracy (OSPREY)
ASCO 2018: A Phase II Trial of Enzalutamide, Docetaxel and Androgen Deprivation Therapy (ENZADA) in Patients with Metastatic Castrate Sensitive Prostate Cancer (mCSPC)
ASCO 2018: The Association of BRCA1 and BRCA2 Mutations on Prostate Cancer Risk, Frequency, and Mortality: Systematic Review and Meta-Analysis
ASCO 2018: The GENTleMEN Study: Genetic Testing for Men with Metastatic Prostate Cancer in Washington State and Beyond
ASCO 2018: Comparing the Occurrence of Major Adverse Cardiovascular Events (MACEs) in Patients with Prostate Cancer and Cardiovascular Disease Receiving Degarelix or Leuprolide
ASCO 2018: Subsequent Treatment after Abiraterone Acetate + Prednisone in Patients with Newly Diagnosed High-Risk Metastatic Castration-naïve Prostate Cancer: LATITUDE
ASCO 2018: Cabazitaxel in mCRPC: Real-life Use, Effectiveness, Safety, and Quality of Life in the FUJI Cohort
ASCO 2018: SPEAR-Bladder (Study Informing Treatment Pathway Decision in Bladder Cancer): First-Through Third-Line Time to Treatment Failure in the US
ASCO 2018: Sipuleucel-T OS and Clinical Outcomes by Baseline PSA Quartiles in Patients with mCRPC: PROCEED Registry
ASCO 2018: Optimal Integration of PARP Inhibitors for Prostate Cancer: Which Test, Which Patient, and Which Therapy?